Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Truist Securities Reiterates Buy on Amneal Pharmaceuticals, Raises Price Target to $9

Author: Benzinga Newsdesk | May 06, 2024 08:32am
Truist Securities analyst Les Sulewski reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $7 to $9.

Posted In: AMRX